| NASDAQ (usa) |
|
6715.56 | -12.11 | -0.18% |
| FTSE 100 (london) |
![]() |
7487.96 | -5.12 | -0.07% |
| DAX (german) |
|
13465.51 | 235.94 | 1.78% |
| NIKKEI 225 (japan) |
|
22420.08 | 408.47 | 1.86% |
| Hang - Seng (hong kong) |
|
28594.06 | 348.52 | 1.23% |
| NIFTY - 50 (india) | ||||
| Straits Times (singapore) |
|
3391.61 | 17.53 | 0.52% |
| KOSPI (korea) |
|
2556.47 | 33.04 | 1.31% |
| All Ordinaries (australia) |
|
6005.30 | 28.90 | 0.48% |
| BOVESPA (brazil) |
|
74092.76 | -215.73 | -0.29% |
Walvax Biotechnology Co. Ltd (SHE: 300142)
300142 Technical Analysis
5
| As on 26th Jan 2026 300142 STOCK Price closed @ 14.48 and we RECOMMEND Strong Buy for LONG-TERM with Stoploss of 11.78 & Strong Buy for SHORT-TERM with Stoploss of 12.52 we also expect STOCK to react on Following IMPORTANT LEVELS. |
300142STOCK Price
| Open | 13.33 | Change | Price | % |
| High | 14.65 | 1 Day | 1.49 | 11.47 |
| Low | 12.99 | 1 Week | 1.95 | 15.56 |
| Close | 14.48 | 1 Month | 3.15 | 27.80 |
| Volume | 227641748 | 1 Year | -0.25 | -1.70 |
| 52 Week High 14.87 | 52 Week Low 9.89 | ||||
SHE China Most Active Stocks
| 002131 | 8.00 | -4.76% |
| 000630 | 7.55 | 10.06% |
| 000981 | 4.74 | -5.58% |
| 000725 | 4.47 | 0.45% |
| 002195 | 9.98 | -5.04% |
| 300058 | 20.74 | 0.92% |
| 002202 | 28.40 | -3.99% |
| 000100 | 5.03 | -0.40% |
| 300017 | 13.78 | 20.03% |
| 000620 | 3.40 | -5.82% |
SHE China Top Gainers Stocks
SHE China Top Losers Stocks
| 300142 Daily Charts |
300142 Intraday Charts |
Whats New @ Bazaartrend |
300142 Free Analysis |
|
|
300142 Important Levels Intraday
| RESISTANCE | 17.68 |
| RESISTANCE | 16.65 |
| RESISTANCE | 16.02 |
| RESISTANCE | 15.38 |
| SUPPORT | 13.58 |
| SUPPORT | 12.94 |
| SUPPORT | 12.31 |
| SUPPORT | 11.28 |
300142 Forecast January 2026
| 4th UP Forecast | 17.74 |
| 3rd UP Forecast | 16.69 |
| 2nd UP Forecast | 16.05 |
| 1st UP Forecast | 15.4 |
| 1st DOWN Forecast | 13.56 |
| 2nd DOWN Forecast | 12.91 |
| 3rd DOWN Forecast | 12.27 |
| 4th DOWN Forecast | 11.22 |
300142 Weekly Forecast
| 4th UP Forecast | 16.33 |
| 3rd UP Forecast | 15.74 |
| 2nd UP Forecast | 15.37 |
| 1st UP Forecast | 15.00 |
| 1st DOWN Forecast | 13.96 |
| 2nd DOWN Forecast | 13.59 |
| 3rd DOWN Forecast | 13.22 |
| 4th DOWN Forecast | 12.63 |
300142 Forecast2026
| 4th UP Forecast | 24.92 |
| 3rd UP Forecast | 21.57 |
| 2nd UP Forecast | 19.5 |
| 1st UP Forecast | 17.43 |
| 1st DOWN Forecast | 11.53 |
| 2nd DOWN Forecast | 9.46 |
| 3rd DOWN Forecast | 7.39 |
| 4th DOWN Forecast | 4.04 |
Walvax Biotechnology Co. Ltd ( SHE China Symbol : 300142 )
Sector : Healthcare And Other Stocks in Same Sector
Sector : Healthcare And Other Stocks in Same Sector
300142 Other Details
| Segment | EQ | |
| Market Capital | 90415497216.00 | |
| Sector | Healthcare | |
| Industry | Drug Manufacturers-Specialty & Generic | |
| Offical website | > echo $website ; ?> | |
300142 Address
![]() |
||
300142 Latest News
300142 Business Profile
Walvax Biotechnology Co., Ltd., a biological pharmaceutical company, researches and develops, produces, and sells bio-medicine products in China. The company offers biomedicines, such as vaccines, blood products, and others. It provides Group A, C meningococcal polysaccharide conjugate vaccine for infants below or equal to 2 years preventing diseases, such as cerebrospinal meningitis and septicemia; Group A and C meningococcal polysaccharide vaccine for in adults and children over the age of 2 years and adults to prevent disease caused by the bacterium Neisseria meningitidis group A or group C; and Group ACYW135 meningococcal polysaccharide vaccine for children above 2 years old to prevent epidemic cerebrospinal meningitis caused by Neisseria meningitidis group A, C, Y, and W135. The company also offers haemophilus influenzae type b conjugate vaccine for children from the age of 2 months to 5 years for the prevention of infectious diseases, including meningitis, pneumonia, septicemia, cellulitis, arthritis, epiglottitis, etc. In addition, it provides diphtheria, tetanus, and acellular pertussis combined vaccine for the prevention of diphtheria, tetanus, and pertussis for individuals from the age of 3 months to 6 years; and 23-valent pneumococcal polysaccharide vaccine for children above 2 years old to prevent pneumococcal disease caused by 23 serotypes. Walvax Biotechnology Co., Ltd. was founded in 2001 and is headquartered in Kunming, China. Address: Building 9A, 19th Floor, Kunming, China, 650106
© 2005-2023 BazaarTrend.com All rights reserved.
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service

